These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 24613008)

  • 21. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
    Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
    AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients.
    Llibre JM; Domingo P; del Pozo MA; Miralles C; Galindo MJ; Viciana I; Moreno S; Schapiro JM; Clotet B
    J Antimicrob Chemother; 2008 Jan; 61(1):206-9. PubMed ID: 17999972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prospective study of highly active antiretroviral therapy in Indian human immunodeficiency virus positive patients.
    Rajesh R; Vidyasagar S; Varma DM; Naik A; Hegde BM; Guddattu V; Kamath A
    Int J Risk Saf Med; 2013 Jan; 25(1):53-65. PubMed ID: 23442298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Criteria for initiating highly active antiretroviral therapy and short-term immune response among HIV-1-infected patients in Côte d'Ivoire.
    Diabaté S; Alary M
    HIV Med; 2009 Nov; 10(10):640-6. PubMed ID: 19659945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial.
    Landman R; Koulla-Shiro S; Sow PS; Ngolle M; Diallo MB; Guèye NF; Le Moing V; Eymard-Duvernay S; Benalycherif A; Charpentier C; Peytavin G; Delaporte E; Girard PM;
    Antivir Ther; 2014; 19(1):51-9. PubMed ID: 23970206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients.
    Burgos J; Crespo M; Falcó V; Curran A; Navarro J; Imaz A; Domingo P; Podzamczer D; Mateo MG; Villar S; Van den Eynde E; Ribera E; Pahissa A
    J Antimicrob Chemother; 2012 Oct; 67(10):2479-86. PubMed ID: 22729925
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAART.
    Bongiovanni M; Chiesa E; Di Biagio A; Meraviglia P; Capetti A; Tordato F; Cicconi P; Biasi P; Bini T; d'Arminio Monforte A
    J Antimicrob Chemother; 2005 Jun; 55(6):1003-7. PubMed ID: 15824089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gender differences in the treatment of HIV infection.
    Floridia M; Giuliano M; Palmisano L; Vella S
    Pharmacol Res; 2008; 58(3-4):173-82. PubMed ID: 18708144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I.
    AIDS; 1994 Jul; 8(7):911-21. PubMed ID: 7946100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
    Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
    J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy.
    Gianotti N; Galli L; Bocchiola B; Cahua T; Panzini P; Zandonà D; Salpietro S; Maillard M; Danise A; Pazzi A; Lazzarin A; Castagna A
    HIV Med; 2013 Mar; 14(3):153-60. PubMed ID: 22994659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study.
    Floridia M; Ravizza M; Masuelli G; Giacomet V; Martinelli P; Degli Antoni A; Spinillo A; Fiscon M; Francisci D; Liuzzi G; Pinnetti C; Marconi AM; Tamburrini E;
    J Antimicrob Chemother; 2014 May; 69(5):1377-84. PubMed ID: 24370933
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients.
    Viard JP; Fagard C; Chaix ML; Rouzioux C; Bouteloup V; Bentata M; de Verdière NC; Pahlavan G; Weiss L; Lévy Y; Chêne G;
    AIDS; 2009 Jul; 23(11):1383-8. PubMed ID: 19461505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort.
    Domingo P; Suárez-Lozano I; Torres F; Teira R; Lopez-Aldeguer J; Vidal F; Muñoz A; Viciana P; Lozano F; Vergara A; Roca B; García Alcalde ML; Cosín J; Terrón A; Galindo MJ; Geijo P; Ribera E; Gonzalez J; Sanchez T; Lacalle JR; Garrido M
    J Antimicrob Chemother; 2008 Jun; 61(6):1348-58. PubMed ID: 18356150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longitudinal trends in antiretroviral use in a cohort of men and women in Ontario, Canada.
    Furler MD; Einarson TR; Walmsley S; Millson M; Bendayan R
    AIDS Patient Care STDS; 2006 Apr; 20(4):245-57. PubMed ID: 16623623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No differences between men and women in adverse drug reactions related to psychotropic drugs: a survey from France, Italy and Spain.
    D'Incau P; Lapeyre-Mestre M; Carvajal A; Donati M; Salado I; Rodriguez L; Sáinz M; Escudero A; Conforti A
    Fundam Clin Pharmacol; 2014 Jun; 28(3):342-8. PubMed ID: 23617454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.